Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Neethu Billy Graham Mariam"'
Autor:
K J Reeves, Nuria Porta, Yee Pei Song, Neethu Billy Graham Mariam, Nuradh Joseph, Nicholas D. James, Ananya Choudhury, Peter Hoskin
Publikováno v:
Oncotarget
One third of patients with bladder cancer present with muscle invasive bladder cancer (MIBC) which has a poor prognosis. International guidelines for the management of MIBC recommend radical cystectomy or bladder-preserving treatment based on radical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::432f50cbe4ffc463977be83ce8cba95a
https://doi.org/10.18632/oncotarget.28023
https://doi.org/10.18632/oncotarget.28023
Autor:
Neethu Billy Graham, Mariam, Victoria, Dunnett-Kane, M Trent, Herdman, Tim, Seers, Daniel, Aldcroft, Sooria, Balasegaram, Rebecca, Davenport, Anthony, Redmond, Cassandra, Ng, Lauren, Wentworth
Publikováno v:
Future Healthc J
INTRODUCTION: Frail, older patients with COVID-19 have an increased risk of hospital admission and death. METHODS: We studied a regional model of care used for older patients with COVID-19 in spring 2020 across three settings: an acute teaching hospi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f47bb3da33b41ea960517ab1d019ba70
https://europepmc.org/articles/PMC8966790/
https://europepmc.org/articles/PMC8966790/
Publikováno v:
Lung Cancer. 165:S43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::829a6e8a1b9e115bf3fc51ede6e1f6f1
https://doi.org/10.1016/s0169-5002(22)00138-6
https://doi.org/10.1016/s0169-5002(22)00138-6
Autor:
Laura Woodhouse, Valentinos Kounnis, Konstantinos Kamposioras, Jamie M J Weaver, Brindley Sonal Hapuarachi, Neethu Billy Graham Mariam, Wasat Mansoor, Rebecca Lee, Richard A Hubner, Fiona Britton, Thomas K. Waddell, Adeel M Khan, Kathleen Connors, Jessica Coyle
Publikováno v:
Journal of Clinical Oncology. 39:4039-4039
4039 Background: Despite potentially curative surgery, long-term survival from OGC remains poor due to high relapse rate. Neoadjuvant (naFLOT) and adjuvant (aFLOT) FLOT is currently standard treatment for resectable OGC based on data from the FLOT-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::539c7d0ef6f47d6ac2bd9884eb5a438b
https://doi.org/10.1200/jco.2021.39.15_suppl.4039
https://doi.org/10.1200/jco.2021.39.15_suppl.4039
Autor:
Natalie Cook, Donna M. Graham, Julie-Anne Scott, Sreeja Aruketty, Matthew G Krebs, Hitesh Mistry, Matt Church, Aidi Adamson-Raieste, Louise Carter, Fiona C Thistlethwaite, Rozana Abdul Rahman, Neethu Billy Graham Mariam
Publikováno v:
Journal of Clinical Oncology. 39:3133-3133
3133 Background: The primary objective of EPCCT (phase I and non-randomised phase II trials) is to determine the safety and tolerability of new therapeutic agents. Response rates (RR) in these trials have typically been reported at around 10-15%. Inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a00d7f83b9864d50dc7ad2a8012c26a3
https://doi.org/10.1200/jco.2021.39.15_suppl.3133
https://doi.org/10.1200/jco.2021.39.15_suppl.3133